The present innovation relates to preparation and application of a robust, porous, three dimensional device for extra-hepatic delivery of human islets of Langerhans together with autologous stromal vascular fraction cells for treatment of patients with type 1 diabetes, and to a process of producing patient-specific devices using 3D Bioprinting with biocompatible hydrogel inks. More particularly, the present innovation uses 3D Bioprinting technology to produce a 3D device in which a patient's own adipose-derived stem cells will be able to improve the viability and efficacy of transplanted islets of Langerhans. Mesenchymal stem cells derived from the adipose tissue secrete components which provide a microenvironment for the islets that prevent cellular stress and result in improved viability of the islets. The advantage of such an implantable device with robust structure which enables extra-hepatic transplantation of islets is biocompatibility which eliminates foreign body reaction and enhanced viability of islets resulting in increased insulin production. The incorporation of autologous stromal vascular fractions promotes vascularization which is an important feature for the device's functionality.